Yury Lopatin - Academia.edu (original) (raw)

Papers by Yury Lopatin

Journal of Cardiovascular Development and Disease, Mar 3, 2022

This article is an open access article distributed under the terms and conditions of the Creative... more This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY

Terapevticheskii arkhiv, 2022

Aim. Study the impact of various combinations of comorbid original diseases in patients infected ... more Aim. Study the impact of various combinations of comorbid original diseases in patients infected with COVID-19 later on the disease progression and outcomes of the new coronavirus infection. Materials and methods. The ACTIV registry was created on the Eurasian Association of Therapists initiative. 5,808 patients have been included in the registry: men and women with COVID-19 treated at hospital or at home. ClinicalTrials.gov ID NCT04492384. Results. Most patients with COVID-19 have original comorbid diseases (oCDs). Polymorbidity assessed by way of simple counting of oCDs is an independent factor in negative outcomes of COVID-19. Search for most frequent combinations of 2, 3 and 4 oCDs has revealed absolute domination of cardiovascular diseases (all possible variants). The most unfavorable combination of 2 oCDs includes atrial hypertension (AH) and chronic heart failure (CHF). The most unfavorable combination of 3 oCDs includes AH, coronary heart disease (CHD) and CHF; the worst com...

European Journal of Heart Failure, 2019

Take-down policy If you believe that this document breaches copyright please contact us providing... more Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

European Heart Journal Supplements, 2019

A 69-year-old man with a history of inferior non-STsegment elevation myocardial infarction treate... more A 69-year-old man with a history of inferior non-STsegment elevation myocardial infarction treated with a percutaneous coronary intervention and stenting of the right coronary artery 3 years ago presented with typical angina (Canadian Cardiovascular Society Class II) lasting for 2 weeks. Prior to this, angina attacks occurred rarely and were immediately resolved by short-acting nitrates. His regular treatment consisted of the following cardiovascular medications: aspirin 100 mg once daily, atorvastatin 20 mg once daily, perindopril 5 mg once daily, and bisoprolol 5 mg once daily. The patient's comorbidities included hypertension, hypercholesterolaemia, and osteoarthritis. On examination, the patient was in sinus rhythm, with a blood pressure of 138/76 mmHg and a heart rate of 68 b.p.m. His cholesterol was 165 mg/dL, low-density lipoprotein 75 mg/dL, high-density lipoprotein 41 mg/dL, triglycerides 180 mg/dL, blood glucose 102 mg/dL, creatinine 0.9 mg/dL, and estimated glomerular filtration rate 84 mL/ min/1.73 m 2. Eelectrocardiography (ECG) at rest revealed a first-degree atrioventricular block without significant ST-T wave changes. Previously, the patient had no prior history of conduction system abnormalities.

European Heart Journal Supplements, 2019

European Heart Journal, 2019

The content of these ESC Guidelines has been published for personal and educational use only. No ... more The content of these ESC Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oxfordjournals.org). Disclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

Cardiac Failure Review, 2015

Metabolic impairments play an important role in the development and progression of heart failure.... more Metabolic impairments play an important role in the development and progression of heart failure. The use of metabolic modulators, the number of which is steadily increasing, may be particularly effective in the treatment of heart failure. Recent evidence suggests that modulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation represents a promising approach to the treatment of patients with heart failure. This review focuses on the role of metabolic modulators, in particular trimetazidine, as a potential additional medication to conventional medical therapy in heart failure.

European Journal of Heart Failure

European Journal of Heart Failure

Circulation, 2017

Introduction: Few trials have demonstrated an improvement in systolic function in patients hospit... more Introduction: Few trials have demonstrated an improvement in systolic function in patients hospitalized with heart failure (HF) after early co-administration of beta-blockers (BBs) and ivabradine. ...

This article focuses on the management of concomitant angina in patients with heart failure, as d... more This article focuses on the management of concomitant angina in patients with heart failure, as described in the 2016 European guidelines for the diagnosis and treatment of acute and chronic heart failure. Trimetazidine has been included in this new guideline because it is considered an effective and safe antianginal treatment in patients with angina and heart failure. It is well-known that impairment of cardiac metabolism plays an important role in the pathophysiology of heart failure. Trimetazidine shifts the myocardial energy metabolism from fatty acid β-oxidation toward glucose oxidation, resulting in a greater production of high-energy phosphates. Adding trimetazidine to a β-blocker (or to an alternative treatment to β-blocker), is considered as an effective and safe step to eliminate angina. Along with this, trimetazidine improves New York Heart Association functional capacity, delays or reverses left ventricular remodeling, and reduces B-type natriuretic peptide levels in hea...

Coronary revascularization procedures (coronary artery bypass grafting and percutaneous coronary ... more Coronary revascularization procedures (coronary artery bypass grafting and percutaneous coronary intervention) take their place among the principal approaches to coronary artery disease (CAD) treatment. These procedures not only successfully alleviate the symptoms of the disease, but may also improve outcome in subsets of CAD patients. However, accumulating data suggest the possibility that myocardial injury develops as a response to the restoration of coronary blood flow. This paper describes the potential benefits of trimetazidine as a promising agent for cardiac protection in patients undergoing coronary revascularization. The rationale for long-term treatment with trimetazidine after coronary revascularization procedures is also discussed.

Patients with heart failure (HF) who contract SARS-CoV-2 infection are at a higher risk of cardio... more Patients with heart failure (HF) who contract SARS-CoV-2 infection are at a higher risk of cardiovascular and non-cardiovascular morbidity and mortality. Regardless of therapeutic attempts in COVID-19, vaccination remains the most promising global approach at present for controlling this disease. There are several concerns and misconceptions regarding the clinical indications, optimal mode of delivery, safety and efficacy of COVID-19 vaccines for patients with HF. This document provides guidance to all healthcare professionals regarding the implementation of a COVID-19 vaccination scheme in patients with HF. COVID-19 vaccination is indicated in all patients with HF, including those who are immunocompromised (e.g. after heart transplantation receiving immunosuppressive therapy) and with frailty syndrome. It is preferable to vaccinate against COVID-19 patients with HF in an optimal clinical state, which would include clinical stability, adequate hydration and nutrition, optimized trea...

Journal of Cardiovascular Development and Disease, Mar 3, 2022

This article is an open access article distributed under the terms and conditions of the Creative... more This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY

Terapevticheskii arkhiv, 2022

Aim. Study the impact of various combinations of comorbid original diseases in patients infected ... more Aim. Study the impact of various combinations of comorbid original diseases in patients infected with COVID-19 later on the disease progression and outcomes of the new coronavirus infection. Materials and methods. The ACTIV registry was created on the Eurasian Association of Therapists initiative. 5,808 patients have been included in the registry: men and women with COVID-19 treated at hospital or at home. ClinicalTrials.gov ID NCT04492384. Results. Most patients with COVID-19 have original comorbid diseases (oCDs). Polymorbidity assessed by way of simple counting of oCDs is an independent factor in negative outcomes of COVID-19. Search for most frequent combinations of 2, 3 and 4 oCDs has revealed absolute domination of cardiovascular diseases (all possible variants). The most unfavorable combination of 2 oCDs includes atrial hypertension (AH) and chronic heart failure (CHF). The most unfavorable combination of 3 oCDs includes AH, coronary heart disease (CHD) and CHF; the worst com...

European Journal of Heart Failure, 2019

Take-down policy If you believe that this document breaches copyright please contact us providing... more Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

European Heart Journal Supplements, 2019

A 69-year-old man with a history of inferior non-STsegment elevation myocardial infarction treate... more A 69-year-old man with a history of inferior non-STsegment elevation myocardial infarction treated with a percutaneous coronary intervention and stenting of the right coronary artery 3 years ago presented with typical angina (Canadian Cardiovascular Society Class II) lasting for 2 weeks. Prior to this, angina attacks occurred rarely and were immediately resolved by short-acting nitrates. His regular treatment consisted of the following cardiovascular medications: aspirin 100 mg once daily, atorvastatin 20 mg once daily, perindopril 5 mg once daily, and bisoprolol 5 mg once daily. The patient's comorbidities included hypertension, hypercholesterolaemia, and osteoarthritis. On examination, the patient was in sinus rhythm, with a blood pressure of 138/76 mmHg and a heart rate of 68 b.p.m. His cholesterol was 165 mg/dL, low-density lipoprotein 75 mg/dL, high-density lipoprotein 41 mg/dL, triglycerides 180 mg/dL, blood glucose 102 mg/dL, creatinine 0.9 mg/dL, and estimated glomerular filtration rate 84 mL/ min/1.73 m 2. Eelectrocardiography (ECG) at rest revealed a first-degree atrioventricular block without significant ST-T wave changes. Previously, the patient had no prior history of conduction system abnormalities.

European Heart Journal Supplements, 2019

European Heart Journal, 2019

The content of these ESC Guidelines has been published for personal and educational use only. No ... more The content of these ESC Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oxfordjournals.org). Disclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

Cardiac Failure Review, 2015

Metabolic impairments play an important role in the development and progression of heart failure.... more Metabolic impairments play an important role in the development and progression of heart failure. The use of metabolic modulators, the number of which is steadily increasing, may be particularly effective in the treatment of heart failure. Recent evidence suggests that modulating cardiac energy metabolism by reducing fatty acid oxidation and/or increasing glucose oxidation represents a promising approach to the treatment of patients with heart failure. This review focuses on the role of metabolic modulators, in particular trimetazidine, as a potential additional medication to conventional medical therapy in heart failure.

European Journal of Heart Failure

European Journal of Heart Failure

Circulation, 2017

Introduction: Few trials have demonstrated an improvement in systolic function in patients hospit... more Introduction: Few trials have demonstrated an improvement in systolic function in patients hospitalized with heart failure (HF) after early co-administration of beta-blockers (BBs) and ivabradine. ...

This article focuses on the management of concomitant angina in patients with heart failure, as d... more This article focuses on the management of concomitant angina in patients with heart failure, as described in the 2016 European guidelines for the diagnosis and treatment of acute and chronic heart failure. Trimetazidine has been included in this new guideline because it is considered an effective and safe antianginal treatment in patients with angina and heart failure. It is well-known that impairment of cardiac metabolism plays an important role in the pathophysiology of heart failure. Trimetazidine shifts the myocardial energy metabolism from fatty acid β-oxidation toward glucose oxidation, resulting in a greater production of high-energy phosphates. Adding trimetazidine to a β-blocker (or to an alternative treatment to β-blocker), is considered as an effective and safe step to eliminate angina. Along with this, trimetazidine improves New York Heart Association functional capacity, delays or reverses left ventricular remodeling, and reduces B-type natriuretic peptide levels in hea...

Coronary revascularization procedures (coronary artery bypass grafting and percutaneous coronary ... more Coronary revascularization procedures (coronary artery bypass grafting and percutaneous coronary intervention) take their place among the principal approaches to coronary artery disease (CAD) treatment. These procedures not only successfully alleviate the symptoms of the disease, but may also improve outcome in subsets of CAD patients. However, accumulating data suggest the possibility that myocardial injury develops as a response to the restoration of coronary blood flow. This paper describes the potential benefits of trimetazidine as a promising agent for cardiac protection in patients undergoing coronary revascularization. The rationale for long-term treatment with trimetazidine after coronary revascularization procedures is also discussed.

Patients with heart failure (HF) who contract SARS-CoV-2 infection are at a higher risk of cardio... more Patients with heart failure (HF) who contract SARS-CoV-2 infection are at a higher risk of cardiovascular and non-cardiovascular morbidity and mortality. Regardless of therapeutic attempts in COVID-19, vaccination remains the most promising global approach at present for controlling this disease. There are several concerns and misconceptions regarding the clinical indications, optimal mode of delivery, safety and efficacy of COVID-19 vaccines for patients with HF. This document provides guidance to all healthcare professionals regarding the implementation of a COVID-19 vaccination scheme in patients with HF. COVID-19 vaccination is indicated in all patients with HF, including those who are immunocompromised (e.g. after heart transplantation receiving immunosuppressive therapy) and with frailty syndrome. It is preferable to vaccinate against COVID-19 patients with HF in an optimal clinical state, which would include clinical stability, adequate hydration and nutrition, optimized trea...